[Featured Stock] Withus Pharm Gains on WHO Recommendation for 'Methylprednisolone' Prescription in Severe COVID-19 Cases

[Asia Economy Reporter Minwoo Lee] Withus Pharmaceutical's stock price is on the rise. This appears to be due to the fact that the World Health Organization (WHO) recommended the use of steroid drugs for severe COVID-19 patients, highlighting the company's related products.

As of 2 PM on the 3rd, Withus Pharmaceutical's stock price recorded 23,950 KRW, up 5.74% from the previous day. After research showed that the mortality rate of COVID-19 patients who took steroid drugs decreased to one-third, WHO recommended the use of steroid drugs, and it was confirmed that Withus Pharmaceutical has the relevant products, which seems to have acted as a positive factor.

According to the Wall Street Journal (WSJ) on the 2nd (local time), a study involving a total of 1,700 COVID-19 patients found that the mortality rate of patients taking steroids was reduced to one-third. The Journal of the American Medical Association reported that 32.7% of 678 severe patients administered steroids died. This figure shows a significant difference compared to the 41.5% mortality rate of patients given a placebo. This result comes from evaluating the use of steroids such as dexamethasone, hydrocortisone, and methylprednisolone through seven studies conducted from February to June. Accordingly, WHO recommended introducing these drugs for severe COVID-19 patients.

Withus Pharmaceutical has been manufacturing Withus Methbone tablets containing 4 milligrams (mg) of methylprednisolone, which was approved by the Ministry of Food and Drug Safety in 2003.

This content was produced with the assistance of AI translation services.